Recombinant R-spondin2 and Wnt3a Up- and Down-Regulate Novel Target Genes in C57MG Mouse Mammary Epithelial Cells

Bolormaa Baljinnyam1, Malgorzata Klawinska2, Saad Saffo1, Robert Callahan2, Jeffrey S. Rubin1*

1 Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland, United States of America, 2 Oncogenetics Section, Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, Bethesda, Maryland, United States of America

Abstract

R-spondins (Rspos) comprise a family of four secreted proteins that have important roles in cell proliferation, cell fate determination and organogenesis. Rspos typically exert their effects by potentiating the Wnt/b-catenin signaling pathway. To systematically investigate the impact of Rspo/Wnt on gene expression, we performed a microarray analysis using C57MG mouse mammary epithelial cells treated with recombinant Rspo2 and/or Wnt3a. We observed the up- and down-regulation of several previously unidentified target genes, including ones that encode proteins involved in immune responses, effectors of other growth factor signaling pathways and transcription factors. Dozens of these changes were validated by quantitative real time RT-PCR. Time course experiments showed that Rspo2 typically had little or no effect on Wnt-dependent gene expression at 3 or 6 h, but enhanced expression at 24 h, consistent with biochemical data indicating that Rspo2 acts primarily to sustain rather than acutely increase Wnt pathway activation. Up-regulation of gene expression was inhibited by pre-treatment with Dickkopf1, a Wnt/b-catenin pathway antagonist, and by siRNA knockdown of b-catenin expression. While Dickkopf1 blocked Rspo2/Wnt3a-dependent down-regulation, a number of down-regulated genes were not affected by b-catenin knockdown, suggesting that in these instances down-regulation was mediated by a b-catenin-independent mechanism.

Introduction

The R-spondin (Rspo) protein family consists of four homologous members that are dynamically expressed during embryogenesis and have important roles in development [1–5]. Rspo2 participates in myogenesis, limb, laryngeal-tracheal and lung morphogenesis, osteoblast maturation and bone mineralization [4,6–9], while Rspo3 is required for placental formation, angioblast and vascular development [10,11]. Mutations in particular Rspo genes cause human syndromes characterized by specific birth defects. For example, loss-of-function Rspo1 mutations result in female-to-male gender reversal due to aberrant ovarian development [12], and Rspo4 point mutations are associated with absent or malformed fingernails and toenails (anonychia) [13,14].

Several lines of evidence have linked Rspo to the Wnt genes. The Wnts comprise a large family of secreted, lipid-modified glycoproteins that have a variety of crucial functions during embryonic development and contribute to tissue homeostasis in the adult [15–17]. Rspo and Wnt genes exhibit overlapping patterns of expression in many tissues during development, including the neural tube and muscle [2–4]. Together they induce myogenesis by stimulating the transcriptional activity of b-catenin [4], a key mediator of Wnt signaling that promotes differentiation or proliferation depending on the context [16]. Administration of Rspo protein to mice elicited a massive proliferative expansion of the small intestines, consistent with a direct effect on Wnt/b-catenin signaling in the crypts [18]. Recombinant Rspo supports the propagation of intestinal crypt and villus structures in three-dimensional ex vivo cultures [19]. Activation of the b-catenin pathway requires Wnt binding to receptors in the Frizzled family and co-receptors, low density lipoprotein receptor-related proteins 5 or 6 (LRP5/6). These interactions trigger phosphorylation of LRP5/6 and disassembly of a b-catenin degradation complex, which allows b-catenin to accumulate in the cytosol and translocate to the nucleus where it functions as a transcriptional co-activator [20,21]. How Rspos enhance signaling through this pathway is uncertain. Reports vary regarding the ability of Rspos to bind Frizzleds, LRP6 or Wnts [22,23]. One group suggested that Rspos inhibit LRP6 internalization and down-regulation [24,25], although others disputed this mechanism [26–28]. Recent articles claim that LGRA4/5/6 (leucine-rich-repeat containing G protein-coupled receptor) function as Rspo receptors and regulate Wnt/b-catenin signaling through association with Wnt receptors [29–31].

The connection between Wnt and Rspo extends to cancer. Wnt1 was identified as a gene that was insertionally activated by the mouse mammary tumor virus (MMTV) [32,33], and subsequently shown to stimulate the formation of adenocarcino-
mas when expressed as a transgene in mouse mammary gland [34]. Expression of Rspo2 and other Rspo family members also was induced by insertion of MMTV into mammary epithelial cell DNA, and similarly associated with tumorigenesis [35,36]. Interestingly, activation of Rspo genes in MMTV-derived tumors was accompanied by independent activation of Wnt or Egf genes, with Rspo2 and Wnt3a expression being the most frequent combination [35]. Moreover, our recent study suggested that Rpos and Wnts cooperate to promote malignant transformation and/or influence tumor behavior of mammary cells [37]. Considering the well-established role of Wnt/β-catenin signaling in several types of cancer [15–17], stimulation of tumorigenesis via this pathway would not be surprising. However, other Wnt pathways also contribute to neoplasia [38,39] and Rspo3 was recently shown to activate JNK signaling [40], suggesting that the proposed cooperation of Rpos and Wnts in cancer might involve other mechanisms as well.

The present study was undertaken to investigate the interaction of Rspo and Wnt in mammary epithelial cells with a primary focus on the regulation of gene expression. We used the C57MG mouse mammary epithelial line as our model system because several earlier reports had characterized Wnt target genes in this setting [41–46], facilitating our analysis of Rspo effects on Wnt-dependent gene expression. In contrast to previous studies that relied on the use of crude Wnt-containing conditioned medium or C57MG cells transfected with Wnt cDNA, we used purified recombinant proteins, Rspo2 and Wnt3a, thus ensuring the specificity of elicited responses and enabling time-course and dose-response experiments. Our investigation revealed the up-regulation and down-regulation of many novel Wnt target genes, which often was enhanced by concomitant Rspo2 addition. Typically up-regulation was mediated by β-catenin, as indicated by inhibition with small interfering RNA (siRNA) that blocked β-catenin expression and the Wnt/β-catenin pathway antagonist Dickkopf 1 (Dkk1) [17]. Interestingly, Dkk1 also inhibited the down-regulation of Wnt3a/Rspo2 target genes, but only a subset of these decreases in expression was disrupted by knockout of β-catenin. This suggested that β-catenin-independent mechanisms elicited by Wnt3a and Rspo2 also control gene expression in mammary epithelial cells.

**Results and Discussion**

**Microarray analysis of Rspo2/Wnt3a-dependent gene expression in C57MG cells**

Initially we monitored the expression of prototypical Wnt target genes ([Axin2, Cnd1, Msh], for accession numbers of genes mentioned in this article see Table S2) by quantitative real-time RT-PCR (qRT-PCR) in time-course and dose-response experiments to optimize conditions for the microarray analysis. Based on these results, C57MG cells were incubated for 24 h with 100 ng/ml Rspo2 or Wnt3a alone or in combination, or with the carrier protein bovine serum albumin (BSA, 16 µg/ml). Total RNA was harvested from triplicate monolayers corresponding to each treatment group as illustrated by a heat map of changes in gene expression being the most frequent combination [35]. Among the immune response genes confirmed by qRT-PCR expression of relatively few genes (14 up-regulated, 90 down-regulated, and most 90) were affected by Wnt3a as well (Figure 1B and 1C). While Wnt3a increased the expression of 72 genes and decreased the expression of 350, an additional 664 transcripts were only altered by the combination of Rspo2 and Wnt3a (Figure 1B and 1C). These results reinforced the idea that Rspo2 and Wnt3a have overlapping and synergistic effects on gene expression.

Characterization of Rspo2/Wnt3a responsive genes according to gene ontology classification showed a strong correlation with development (183 genes, P-value 2.06E-09) and signal transduction (211 genes, P-value 1.08E-06). This was not surprising given the established association of Rpos and Wnts with these biological processes. However, the diversity of subcategories within these groups was noteworthy, implying potential relevance beyond mammary cell biology and extensive crosstalk with other signaling pathways (Table S1). Unexpectedly, there was an even stronger link to genes involved in immune response (89 genes, P-value 1.15E-19), including innate immunity and inflammation (Table S1). While contributions of Wnt signaling to the development and function of the immune system have been described [48,49], many of the immune response genes detected in our microarray analysis were not previously associated with Wnt or Rspo regulation and therefore suggest novel mechanisms of immune regulation. In addition to these gene ontology categories, several putative Rspo2/Wnt target genes were classified among various metabolic processes (Table S1). Interestingly, Wnt/β-catenin signaling was recently reported to control the hepatic expression of genes that mediate gluconeogenesis [50].

**Validation of known and novel target genes**

We verified the expression pattern of several dozen genes by qRT-PCR (Table S2), confirming the reliability of the microarray analysis. In a few instances the magnitude of change in gene expression elicited by Rspo2 and/or Wnt3a relative to BSA differed in qRT-PCR vs. microarray analysis, but the overall pattern was similar in a large majority of the genes examined. We observed the up-regulation of several previously identified Wnt/β-catenin target genes including those encoding [Axin2, Cnd1, Msh], Ctgf, Efhb2 and Twist1 (Table 1). While the expression of these genes is mediated by β-catenin/TCF complexes, we also observed changes that involved β-catenin interactions with other transcription factors such as the retinoic acid receptor-dependent, up-regulation of Espp2/autotaxin [51]. Of note, many of the changes in gene expression confirmed in C57MG cells also were verified by qRT-PCR in another mouse mammary epithelial cell line, NOG-8 (data not shown). Because the regulation of several previously documented Wnt target genes was common to cells from other organs, we suspect that at least some of the new data obtained in the present microarray analysis is likely to be relevant to other tissues and cell types. Interestingly, Rspo2 strongly enhanced the β-catenin-dependent activity of Wnt4 in C57MG cells, which by itself was low compared to Wnt3a. However, a combination of Rspo2 and Wnt3a was unable to stimulate [Axin2 expression in C57MG cells, consistent with the general lack of Wnt3a activity in the β-catenin pathway.

Among the immune response genes confirmed by qRT-PCR (Table 2), the increase in expression of the chemokine receptor CXCR6 was of particular interest because of its association with
mammary and prostate cancer [52–55]. Lin et al. reported that CXCR6 expression is mediated by HIF1α and contributes to breast cancer metastasis [55]. HIF1α is another transcription factor that acts in concert with β-catenin to regulate a set of target genes [56]; perhaps such cooperation controls CXCR6 expression as well. The striking increase in interleukin 33 (IL33) also was noteworthy. Although originally associated with T cell activation, IL33 subsequently has been shown to act on a variety of cell types [57]. In contrast to CXCR6 and IL33, the chemokines CCL5 and CCL7 were down-regulated by Wnt3a alone and in combination with Rspo2. Both Rspo2 and Wnt3a inhibited the expression of several acute phase reactants (Saa3, C3, Hp and Lcn2), in some instances by >90%. While some changes in expression of immune response genes such as CXCR6 presumably have a direct effect on mammary epithelial cells, others might regulate immune function in the microenvironment. Alternatively, Saa3 expressed by the bovine mammary gland is transmitted in milk and thought to facilitate immune function in the offspring [58].

Potential crosstalk between Wnt/Rspo and other growth factor signaling mechanisms was implicit in the synergistic up-regulation of multiple genes that participate in insulin/IGF, TGFβ and FGF pathways (Table 3). One of these genes, IRS1, also was identified as a pathophysiologically relevant Wnt/β-catenin target gene in colorectal carcinomas [59]. Up-regulation of insulin/IGF pathway genes, including IGF1, is provocative given the association of IGF

![Figure 1. Schematic summary of Rspo2/Wnt3a-dependent gene expression in C57MG cells.](image)

**Table 1.** Microarray data of known Wnt/β-catenin target genes validated by qRT-PCR.

| Gene   | Rsps2 Fold change | Rsps2 P value | Wnt3a Fold change | Wnt3a P value | Wnt3a/Rspo2 Fold change | Wnt3a/Rspo2 P value |
|--------|------------------|---------------|-------------------|---------------|-------------------------|---------------------|
| Axin2  | 0.75             | 0.44          | 1.53              | 0.17          | 21.62                   | 0.01                |
| Rhou   | 0.99             | 0.96          | 2.22              | 0.01          | 12.78                   | 0.15E-2             |
| Enpp2  | 0.75             | 0.19          | 1.92              | 0.02          | 9.21                    | 0.95E-3             |
| Ahr    | 1.02             | 0.82          | 2.1               | 0.67E-3       | 7.24                    | 0.00E-3             |
| Ifi5   | 1.45             | 0.01          | 2.23              | 0.34E-2       | 5.06                    | 0.76E-2             |
| Edn1   | 1.41             | 0.01          | 2.18              | 0.19E-2       | 4.22                    | 0.19E-5             |
| Ccnd1  | 1.39             | 0.08          | 2.12              | 0.02          | 3.28                    | 0.02                |
| Msln   | 1.14             | 0.03          | 1.82              | 0.39E-2       | 2.91                    | 0.23E-4             |
| Ctgf   | 1.24             | 0.06          | 1.84              | 0.11E-2       | 2.52                    | 0.67E-3             |
| Efna2  | 1.47             | 0.02          | 1.82              | 0.03          | 2.3                     | 0.13E-2             |
| Twist1 | 1.19             | 0.02          | 1.27              | 0.09          | 2.04                    | 0.015               |

Fold change relative to level in cells treated with BSA. doi:10.1371/journal.pone.0029455.t001

| Gene   | Rsps2 Fold change | Rsps2 P value | Wnt3a Fold change | Wnt3a P value | Wnt3a/Rspo2 Fold change | Wnt3a/Rspo2 P value |
|--------|------------------|---------------|-------------------|---------------|-------------------------|---------------------|
| IL33   | 5.11             | 0.19E-2       | 11.03             | 0.22E-2       | 33.54                   | 0.36E-4             |
| CXCR6  | 0.74             | 0.65          | 2.96              | 0.04          | 22.84                   | 0.67E-5             |
| TGFβ2  | 1.11             | 0.39          | 1.62              | 0.09          | 4.38                    | 0.05                |
| Inhib1 | 1.40             | 0.06          | 2.00              | 0.52E-3       | 3.74                    | 0.01                |
| TGFβR2 | 1.03             | 0.77          | 1.89              | 0.05          | 3.20                    | 0.03                |
| CCL5   | 0.69             | 0.05          | 0.58              | 0.21E-2       | 0.38                    | 0.39E-3             |
| IFR7   | 0.71             | 0.32E-3       | 0.40              | 0.14E-3       | 0.28                    | 0.11E-2             |
| CCL7   | 0.40             | 0.12E-2       | 0.31              | 0.15E-2       | 0.13                    | 0.11E-2             |
| Saa3   | 0.08             | 0.18E-2       | 0.09              | 0.75E-3       | 0.11                    | 0.20E-3             |
| C3     | 0.22             | 0.10E-3       | 0.12              | 0.39E-3       | 0.06                    | 0.40E-3             |
| Hp     | 0.16             | 0.11E-2       | 0.02              | 0.53E-2       | 0.03                    | 0.51E-2             |
| Lcn2   | 0.05             | 0.31E-2       | 0.02              | 0.29E-2       | 0.01                    | 0.29E-2             |

Fold change relative to level in cells treated with BSA. doi:10.1371/journal.pone.0029455.t002
signaling and breast cancer [60]. Numerous studies have described interactions between Wnt and TGFβ or Wnt and FGF signaling [61,62]. The present data extend these observations by suggesting that Wnt/Rspo signaling regulates the expression of various effectors in these growth factor pathways.

We verified that Rspo2 and/or Wnt3a controlled the expression of several transcription factors (Table 4). Klf5 had been identified as a Wnt target gene in multiple settings including C57MG cells [45,46], while the up-regulation of Helt was a novel finding as was the down-regulation of Klf15, IRF7 and Stat1 (Table 4). Many other confirmed, previously unrecognized Wnt target genes are listed in Table 5. Included in this group are genes encoding the tyrosine kinases HCK and Tec, angiopeptin1 and angiopeptin-like4, and inscuteable, a mediator of cell polarity.

Induction of the aryl hydrocarbon receptor (Ahr) by Wnt3a and Rspo2 was especially noteworthy. Though described as a Wnt target gene in a few prostate carcinoma lines [63], this relationship had not been noted elsewhere. Ahr was first identified as the dioxane receptor and associated with its carcinogenic and other toxic effects. Subsequently Ahr was recognized as a transcription factor that bound endogenous or xenobiotic ligands and heterodimerized with Arnt/HIF2 to activate the expression of genes such as Cyp1a1 [64]. More recently Ahr was shown to function as an E3 ubiquitin ligase that targeted the estrogen and androgen receptors for degradation [65,66], an activity that might be exploited in cancer therapy [67,68]. Remarkably, Ahr also serves as an E3 ubiquitin ligase for β-catenin and treatment with natural Ahr ligands suppressed intestinal carcinogenesis in ApcMin/+ mice [69]. This implied that the up-regulation of Ahr could provide a mechanism to suppress tumorigenesis by administering Ahr ligands. Such an approach might be useful for the treatment and/or chemoprevention of colorectal, breast and perhaps other cancers. Conversely, Ahr ligand stimulated the expression of Rspo1 in a zebrafish model of regenerating fin, and thereby enhanced Wnt/β-catenin signaling [70]. Other recent articles have described an interplay of Ahr and Wnt/β-catenin signaling that results in either increase or decrease in target gene expression [71,72]. It appears that the ability of Ahr to promote or impede β-catenin transcriptional activity is context-specific.

Rspo2 promotes Wnt3a-dependent gene expression by prolonging β-catenin pathway activation

Time-course experiments with recombinant Wnt3a indicated that gene expression typically was increased at 3 h, reached a peak at 6 h and was reduced at 24 h (Figure 2A). Rspo2 had minor effects on its own or with Wnt3a at 3 and 6 h, but it markedly enhanced expression of transcript at 24 h (Figure 2A). Though stimulation was not as dramatic at the protein level, immunoblot analysis confirmed the up-regulation of Klf15 and Ahr, with the effect of Rspo2 evident at 24 h (Figure 2B). The doublet bands in the Klf15 blot probably reflected differential post-translational modification, which had been previously described [73]. Similar observations about the timing of responses to Rspo2 and Wnt3a were made with standard biochemical readouts of β-catenin pathway activation. Rspo2 alone elicited only a small increase in

### Table 3. Microarray data of genes in other growth factor signaling pathways.

| Gene    | Rspo2 Fold change | Rspo2 P value | Wnt3a Fold change | Wnt3a P value | Wnt3a/Rspo2 Fold change | Wnt3a/Rspo2 P value |
|---------|------------------|--------------|-------------------|--------------|------------------------|---------------------|
| Grib1p2 | 0.99             | 0.98         | 2.64              | 0.02         | 8.82                   | 0.57E-2             |
| TGFβ2   | 1.11             | 0.39         | 1.62              | 0.09         | 4.38                   | 0.05                |
| Spry1   | 1.64             | 0.49E-2      | 2.42              | 0.21E-3      | 4.20                   | 0.42E-4             |
| IGFl    | 1.31             | 0.28         | 2.04              | 0.53E-2      | 3.21                   | 0.81E-2             |
| TGFβR2  | 1.03             | 0.77         | 1.89              | 0.05         | 3.20                   | 0.03                |
| R53     | 1.08             | 0.53         | 1.71              | 0.67E-2      | 3.06                   | 0.17E-2             |
| FGFR5   | 1.08             | 0.27         | 1.17              | 0.45         | 2.47                   | 0.54E-2             |
| FGFR2   | 1.43             | 0.32         | 2.35              | 0.48E-2      | 2.37                   | 0.07                |

Fold change relative to level in cells treated with BSA. doi:10.1371/journal.pone.0029455.t003

### Table 4. Microarray data of transcription factor genes validated by qRT-PCR.

| Gene    | Rspo2 Fold change | Rspo2 P value | Wnt3a Fold change | Wnt3a P value | Wnt3a/Rspo2 Fold change | Wnt3a/Rspo2 P value |
|---------|------------------|--------------|-------------------|--------------|------------------------|---------------------|
| Helt    | 1.48             | 0.97         | 2.97              | 0.31E-2      | 7.80                   | 0.16E-2             |
| Ahr     | 1.02             | 0.82         | 2.10              | 0.67E-3      | 7.24                   | 0.89E-3             |
| Klf5    | 1.45             | 0.01         | 2.23              | 0.34E-2      | 5.06                   | 0.76E-2             |
| TCF4    | 1.29             | 0.59E-2      | 1.39              | 0.01         | 2.20                   | 0.01                |
| Nanog   | 2.05             | 0.73E-2      | 1.88              | 0.02         | 2.18                   | 0.45E-2             |
| Klf15   | 0.50             | 0.01         | 0.43              | 0.33E-2      | 0.30                   | 0.39E-3             |
| IRF7    | 0.71             | 0.32E-3      | 0.40              | 0.14E-3      | 0.28                   | 0.11E-2             |
| Stat1   | 0.50             | 0.04         | 0.31              | 0.02         | 0.22                   | 0.02                |

Fold change relative to level in cells treated with BSA. doi:10.1371/journal.pone.0029455.t004

### Table 5. Microarray data of additional novel target genes validated by qRT-PCR.

| Gene    | Rspo2 Fold change | Rspo2 P value | Wnt3a Fold change | Wnt3a P value | Wnt3a/Rspo2 Fold change | Wnt3a/Rspo2 P value |
|---------|------------------|--------------|-------------------|--------------|------------------------|---------------------|
| Pgf1bp2 | 1.52             | 0.07         | 4.30              | 0.88E-2      | 16.34                  | 0.12E-2             |
| HCK     | 1.13             | 0.79         | 3.49              | 0.02         | 13.46                  | 0.97E-2             |
| Tsap18  | 0.90             | 0.77         | 1.56              | 0.16         | 12.19                  | 0.27E-4             |
| Tec     | 0.93             | 0.68         | 2.68              | 0.03         | 11.54                  | 0.29E-2             |
| Chima1  | 1.32             | 0.42         | 1.94              | 0.13         | 6.29                   | 0.79E-2             |
| Klf30   | 1.66             | 0.17         | 2.23              | 0.43E-3      | 6.13                   | 0.41E-5             |
| Inv     | 1.55             | 0.13E-2      | 2.79              | 0.35E-3      | 5.64                   | 0.12E-2             |
| Epac1   | 0.92             | 0.26         | 2.71              | 0.01         | 4.83                   | 0.12E-5             |
| Igfb1   | 2.15             | 0.06         | 2.59              | 0.91E-2      | 4.45                   | 0.54E-3             |
| FHL1    | 1.34             | 0.09         | 2.48              | 0.01         | 3.26                   | 0.31E-2             |
| Wnt9a   | 1.16             | 0.52         | 1.48              | 0.15         | 2.97                   | 0.21E-2             |
| Rnd3    | 1.15             | 0.39E-2      | 1.33              | 0.02         | 2.33                   | 0.21E-2             |
| Sax9    | 1.14             | 0.19         | 0.66              | 0.08         | 0.42                   | 0.31E-2             |
| Angptl4 | 0.43             | 0.04         | 0.25              | 0.01         | 0.33                   | 0.01                |
| Smoc1   | 0.97             | 0.76         | 0.59              | 0.03         | 0.26                   | 0.34E-2             |
| Angpt1  | 0.89             | 0.18         | 0.42              | 0.80E-3      | 0.17                   | 0.17E-2             |

Fold change relative to level in cells treated with BSA. doi:10.1371/journal.pone.0029455.t005
phosphorylated LRP5/6 and the accumulation of β-catenin protein (Figure 3). However, Rspo2 enhanced the activity of Wnt3a in these assays at 24 h (Figure 3). These results demonstrated that the addition of Rspo2 to Wnt3a caused a more sustained activation of the β-catenin pathway, reinforcing our findings with HEK293/STF cells and a truncated Rspo2 derivative [28].

Proof that the β-catenin pathway was responsible for the up-regulation of validated target genes came from experiments involving Dkk1, an antagonist of this pathway, and small interfering RNA knockdown of Ctnnb1 (siCtnnb1), the gene encoding β-catenin. Pre-treatment of C57MG cells with recombinant Dkk1 inhibited the stabilization of β-catenin protein (Figure 4A) and blocked the up-regulation of genes induced by the combination of Rspo2 (10 ng/ml) and Wnt3a (100 ng/ml) (Figure 4B–4D and Table S3). Targeting expression with siCtnnb1 decreased the amount of β-catenin protein in the absence of growth factor and blocked its accumulation in response to Rspo2 plus Wnt3a (Figure 5A). As with Dkk1, β-catenin knockdown disrupted the induction of Axin2, Ahr and CXCR6 mRNA (Figure 5B–5D) as well as other gene transcripts (Table S4). Similar results were obtained with two independent siCtnnb1 reagents (data not shown). Taken together, these data established that the up-regulation of Rspo2/Wnt3a target genes was mediated by the β-catenin pathway and Rspo2 potentiated expression by extending the duration of pathway activation.

Down-regulation of genes by Wnt3a is rapid, Dkk1-sensitive and occurs via either a β-catenin-dependent or -independent mechanism

Time-course analysis of genes down-regulated by Wnt3a and Rspo2 showed that responses were evident at 3 h and sometimes even at 1 h, with maximal or near maximal inhibition seen at 6 h (Figure 6). In general, the effect of Rspo2 plus Wnt3a was not much stronger than that of Wnt3a alone, although Rspo2 alone often had significant inhibitory activity. It is possible that the inhibitory effect of Rspo2 was dependent on low levels of endogenous Wnt expression, while Wnt3a at 100 ng/ml was sufficient for a near-maximal effect. As with the up-regulated genes, pre-treatment of C57MG cells with Dkk1 blocked much if not all of the Rspo2/Wnt3a activity in the qRT-PCR analysis (Figure 7A and Table S3). However, β-catenin knockdown only disrupted the down-regulation of two genes analyzed, Angpt1 and Smoc1, while having little effect on the others (Figure 7B and

Figure 2. Time-course of Rspo2- and Wnt3a-dependent gene up-regulation in C57MG cells. (A) Quantitative RT-PCR analysis of specific gene expression in response to Rspo2 (100 ng/ml) alone (blue), Wnt3a (100 ng/ml) alone (green) or the two together (red) at the indicated time points. Data are the means ± S.D. (error bars, sometimes too small to see) of triplicate measurements from one of several experiments with similar results. (B) Immunoblot analysis of Klf5 and Ahr protein expression following treatment with BSA carrier, Rspo2 (100 ng/ml), Wnt3a (100 ng/ml) alone or in combination for the indicated periods. Membranes were re-probed for Hsp70 as a loading control.

doi:10.1371/journal.pone.0029455.g002
Knockdown of β-catenin showed similar effects in cells treated with Rspo2 or Wnt3a alone (data not shown). These results implied that β-catenin was not involved in the down-regulation of most genes identified as Rspo2/Wnt targets in this study.

Typically Wnt-dependent, β-catenin-mediated gene expression has been associated with stimulation of gene expression. These effects require interaction with other transcription factors such as the DNA-binding TCF family members, as well as retinoic acid receptor, vitamin D receptor or HIF1α [15–17,42,51,56,74]. Relatively little is known about the mechanisms responsible for the down-regulation of gene expression by Wnts and/or β-catenin. There is one report indicating that Wnt/β-catenin suppression of N-Acetylglucosaminyltransferase III expression is associated with TCF binding sites in the promoter region [75].

Particularly intriguing was the observation that most of the decreases in gene expression induced by Rspo2/Wnt3a were Dkk1-sensitive and yet β-catenin-independent. While we cannot exclude the possibility that residual low levels of β-catenin following siCtnnb1 treatment had participated in the inhibitory process, these results suggest that Dkk1 might function in a manner that does not involve a decline in β-catenin protein levels. We were unable to ascertain whether LRP5/6 were required for the de-repression of gene expression by Dkk1 because repeated efforts to simultaneously knockdown expression of LRP5/6 in C57MG cells were unsuccessful. Thus, the present results raise the possibility that the effects of Dkk1 on the suppression of gene expression are associated with TCF binding sites in the promoter region [75].

Figure 3. Time-course of Rspo2- and Wnt3a-dependent LRP5/6 phosphorylation and β-catenin stabilization. C57MG cells were treated with BSA, Rspo2 (100 ng/ml), Wnt3a (100 ng/ml) alone or in combination for the indicated periods. Cell lysates (30 μg protein/lane) were immunoblotted for phosphorylated LRP5/6, total LRP5, total LRP6 and Hsp70, the latter serving as a loading control. Soluble β-catenin was measured by immunoblotting after pull-down with GST-E-cadherin.

Figure 4. Dkk1 inhibited up-regulation of genes by Rspo2 and Wnt3a. (A) Immunoblot analysis of total β-catenin (cell lysate, 30 μg protein/lane) and soluble β-catenin (GST-E-cadherin pull-down) from C57MG cells incubated for 3 h with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml), with or without 20 min Dkk1 (1 μg/ml) pre-treatment. Western blot of Hsp70 was loading control. (B–D) Quantitative PCR analysis of Axin2, Ahr and CXCR6 expression by C57MG cells after 24 h incubation with BSA or Rspo2 plus Wnt3a, with or without Dkk1 pre-treatment (experiment performed in parallel with (A), using the same reagent concentrations). Results are means +/- S.D. of triplicate measurements from one of four representative experiments.
expression by Rspo2/Wnt3a might occur by a novel mechanism distinct from disruption of the canonical Wnt/β-catenin pathway. Elucidation of the mechanisms responsible for Rspo2/Wnt3a-dependent decreases in gene expression and the manner in which the decreases were blocked by Dkk1 should be provocative areas for future research.

**Materials and Methods**

**Reagents**

Recombinant mouse Wnt3a (cat. no. 1324-WN), human R-spondin2 (cat. no. 3266-RS), mouse Dkk1 (cat. no. 5897-DK), mouse Wnt4 (cat. No. 475-WN) and mouse Wnt5a (cat. No. 645-

---

**Figure 5. Knockdown of β-catenin inhibited up-regulation of genes by Rspo2 and Wnt3a.** (A) C57MG cells were pre-treated with either luciferase or pooled Ctnnb1 siRNA reagent for 24 h prior to additional 24 h incubation with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml). Total and soluble β-catenin and Hsp70 were detected as described in Fig. 4 legend. (B–D) Quantitative PCR analysis of Axin2, Ahr and CXCR6 expression by C57MG cells after 24 h incubation with luciferase or pooled Ctnnb1 siRNA reagent followed by 24 h treatment with BSA or Rspo2 plus Wnt3a [experiment performed in parallel with (A), using the same reagent concentrations]. Results are means +/- S.D. of triplicate measurements from one of three representative experiments. doi:10.1371/journal.pone.0029455.g005

**Figure 6. Time-course of Rspo2- and Wnt3a-dependent gene down-regulation in C57MG cells.** Quantitative PCR analysis of specific gene expression in response to Rspo2 (100 ng/ml) alone (blue), Wnt3a (100 ng/ml) alone (green) or the two together (red) at the indicated time points. Data are the means +/- S.D. (error bars, sometimes too small to be seen) of triplicate measurements from one of several experiments with similar results. doi:10.1371/journal.pone.0029455.g006
WN) were purchased from R&D Systems (Minneapolis, MN). Anti-β-catenin antibody (cat. no. 610154) was from BD Biosciences (San Jose, CA). Anti-LRP6 (cat. no. 2560) and anti-phospho-LRP6 (Ser1490; also recognizes pLRP5) (cat. no. 2568) antibodies were from Cell Signaling Technology (Danvers, MA). Anti-LRP5 (cat. no. 365400) was from Invitrogen (Carlsbad, CA). Anti-Klf5 (cat. no. ab24331) and Anti-Ahr (cat. no. ab2770) were purchased from Abcam (Cambridge, MA). Antibody against heat shock protein-70 (Hsp70, sc-7298) was from Santa Cruz Biotechnology (Santa Cruz, CA).

Cell culture
C57MG mouse mammary epithelial cells [41], a gift from the Varmus lab, were cultured in DMEM (cat. no. 11995, Invitrogen) supplemented with 10% fetal bovine serum and 10 \( \mu \)g/ml insulin (cat. no. 12585-014, Invitrogen) and incubated in 5% CO2 at 37°C.

Microarray analysis
C57MG cells were seeded in 6-well plates (2.5 \( \times \) 105 cells/well). After an overnight incubation growth medium was replaced with DMEM lacking supplements, and cells were treated for 24 h with recombinant mouse Wnt3a (100 ng/ml) or recombinant human Rspo2 (100 ng/ml) alone or in combination. For the vehicle control, cells were treated with BSA (16 \( \mu \)g/ml) (cat. no. 81-068-3, Millipore, Kankakee, IL). Each treatment group was prepared in triplicate. Cells were harvested in PBS and snap-frozen on dry ice.

RNA isolation, microarray data generation and data analysis were performed by GenUs Biosystems, Northbrook IL. Total RNA was extracted using RiboPure RNA isolation kit from Ambion (Invitrogen). RNA integrity and quality were assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies). Alexa-555-labeled cRNA was prepared by linear amplification of the poly(A)+ RNA population within the total RNA sample. Briefly, 1 \( \mu \)g of total RNA was reverse transcribed after priming with a DNA oligonucleotide containing the T7 RNA polymerase promoter 5’ to a d(T)24 sequence. After second-strand cDNA synthesis and purification of double-stranded cDNA, in vitro transcription was performed using T7 RNA polymerase. The quantity and quality of the cRNA was determined by spectrophotometry and with an Agilent 2100 Bioanalyzer. One \( \mu \)g of purified cRNA was fragmented to uniform size and applied to Mouse Whole Genome 4 \( \times \) 44 k arrays (Design ID no. 014868; Agilent Technologies) in hybridization buffer. Arrays were hybridized at 37°C for 18 h in a rotating incubator, washed, and scanned with a G2565 Microarray Scanner (Agilent Technologies). Arrays were processed with Agilent Feature Extraction v9.5.3.1 software and data were analyzed with GeneSpring GX v7.3.1 software (both Agilent Technologies). Raw and normalized data can be accessed in Gene Expression Omnibus, consistent with MIAME guidelines (www.ncbi.nlm.nih.gov/geo/; accession number GSE32096). To compare individual expression values across arrays, raw intensity data from each gene was normalized to the 75th percentile intensity of each array. Only genes with values greater than background intensity in all replicates of at least one condition were used for further analysis. Volcano plots were used to filter for differentially expressed genes \( \geq \)2 fold and \( p \)-values <0.05. \( p \)-values were calculated using a two-sample T-test assuming unequal variance.

Quantitative real-time RT-PCR (qRT-PCR)
Cells were seeded in 6-well plates (2.5 \( \times \) 105 or 5 \( \times \) 105 cells per well) and incubated for 24 h. Growth medium was replaced with DMEM lacking supplements 30 min prior to treatment with BSA (16 \( \mu \)g/ml), Wnt3a (100 ng/ml) or Rspo2 (100 ng/ml) and Wnt3a (100 ng/ml) for the indicated times. In experiments involving Dkk1, cells were incubated with Dkk1 (1 \( \mu \)g/ml) for 20 min at 37°C prior to the addition of other proteins.

Figure 7. Contrasting effects of Dkk1 and β-catenin knockdown on representative genes down-regulated by Rspo2 and Wnt3a. (A) Quantitative RT-PCR analysis of Angpt1 and CCL7 expression following 24 h incubation with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml), with or without Dkk1 (1 \( \mu \)g/ml) pre-treatment. (B) Quantitative RT-PCR analysis of Angpt1 and CCL7 expression following 24 h incubation with BSA or Rspo2 (10 ng/ml) plus Wnt3a (100 ng/ml) after pre-treatment with siLuc vs. siCtnnb1. Results in (A) and (B) are means +/- S.D. of triplicate measurements from one of three representative experiments performed simultaneously with experiments illustrated in Figures 4 and 5.

doi:10.1371/journal.pone.0029455.g007
Total RNA was isolated with RNeasy kit (Qiagen) and treated with DNase I (cat. no. 18068-015, Invitrogen) for 15 min at room temperature followed by incubation with 2.5 mM EDTA for 10 min at 65°C to eliminate contamination by genomic DNA. Co-application reverse transcription was carried out as described previously [76] with the SuperScript III First-Strand Synthesis System for RT-PCR (cat. no. 18080-051, Invitrogen). Primers for qRT-PCR (Table S5) were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/). The specificity of each primer pair was analyzed by agarose gel electrophoresis and confirmed by a single band with the appropriate size. The qRT-PCR was performed with Brilliant SYBR Green QPCR Master Mix (cat. no. 600548, Agilent Technologies). For each reaction 80 ng cDNA and 2 μl of 10 μM primer set were combined with 2× master mix to a final volume of 20 μl. The reactions were analyzed in triplicate using the Mx3005P QPCR machine (Agilent Technologies) with the following settings: 10 min incubation at 95°C followed by a three-step cycling program with 40 cycles of 30 sec at 95°C, 60 sec at 60°C and 30 sec at 72°C. To verify the specificity of the reaction a dissociation program was run following the manufacturer’s protocol. Quantification of 18S-RNA and/or β-actin in each CDNA sample was done to normalize the results. Data analysis was performed with MxPro software.

siRNA transfection

C57MG cells were transfected with the Neon Transfection System (Invitrogen) according to the manufacturer’s protocol. Briefly, 10^6 cells were placed in 100 μl resuspension buffer and combined with 200 pmol siRNA. Double-stranded short interfering RNAs targeting mouse β-catenin (cat. no. GS12387) were purchased from Qiaogen (Valencia, CA). In some experiments we combined with 200 pmol siRNA. Double-stranded short interfering RNAs were reverse transcribed and electroporated into Immobilon-P membranes (Millipore) that were blocked with 5% nonfat dried milk dissolved in TTBS (20 mM Tris-HCl, pH 8.0, 0.05% Tween 20, 150 mM NaCl), incubated with primers overnight at 4°C, and subsequently incubated with horseradish peroxidase-labeled secondary antibody. The proteins were visualized with SuperSignal Pico or Femto chemiluminescent reagents (Thermo Scientific) using BioMax films (Eastman Kodak Co., Rochester, NY). For detection of soluble β-catenin, a glutathione S-transferase/E-cadherin pull-down protocol was followed as previously described [77].

Immunoblotting

Treatment conditions were the same as described above (see RNA isolation and reverse transcription). After incubation with recombinant proteins cells were washed twice with phosphate buffered saline (PBS) and lysed with buffer containing 50 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100 and protease inhibitor cocktail (cat. no. 04693124001, Roche Diagnostics, Indianapolis, IN). The cell lysates were clarified by a centrifugation at 20,000 g for 10 min at 4°C. For SDS-PAGE of cell lysates, protein concentration was determined with a Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA), and 30 μg protein was loaded per lane. Depending on size of protein a 4–20% or 10% SDS-polyacrylamide Tris-HCl gel (Criterion Precast Gel; Bio-Rad Laboratories) was used. Proteins were transferred to Immobilon-P membranes (Millipore) that were blocked with 5% nonfat dried milk dissolved in TTBS (20 mM Tris-HCl, pH 8.0, 0.05% Tween 20, 150 mM NaCl), incubated with primary antibody overnight at 4°C, and subsequently incubated with horseradish peroxidase-labeled secondary antibody. The proteins were visualized with SuperSignal Pico or Femto chemiluminescent reagents (Thermo Scientific) using BioMax films (Eastman Kodak Co., Rochester, NY). For detection of soluble β-catenin, a glutathione S-transferase/E-cadherin pull-down protocol was followed as previously described [77].

Supporting Information

Table S1 Gene enrichment within gene ontology classifications following treatment of C57MG cells with Rspo2 and Wnt3a.
(XLS)

Table S2 qRT-PCR analysis of gene expression in C57MG cells treated with Rspo2 and Wnt3a alone or combined.
(XLS)

Table S3 Dkk1 inhibition of gene expression in C57MG cells treated with Rspo2 and Wnt3a.
(XLS)

Table S4 siRNA regulation of gene expression in C57MG cells treated with Rspo2 and Wnt3a or BSA alone.
(XLS)

Table S5 Sequences of primers used in RT-PCR analysis.
(DOC)

Acknowledgments

We thank Dr. Harold Varmus for providing the C57MG cells, and GenUs Biosystems (Northbrook, IL) for microarray and bioinformatic analysis.

Author Contributions

Conceived and designed the experiments: BB RC JSR. Performed the experiments: BB SS. Analyzed the data: BB JSR. Contributed reagents/materials/analysis tools: MK. Wrote the paper: BB MK RC JSR.

References

1. Chen JZ, Wang S, Tang R, Yang Q, Zhao E, et al. (2002) Cloning and identification of a cDNA that encodes a novel human protein with thrombospondin type I repeat domain, hPWTSR. Mol Biol Rep 29: 287–292.
2. Kamata T, Katsube K, Mishikawa M, Yamada M, Takada S, et al. (2004) R-spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutants. Biochim Biophys Acta 1676: 51–62.
3. Nam JS, Turcotte TJ, Yoon JK. (2007) Dynamic expression of R-spondin family genes in mouse development. Gene Expr Patterns 7: 306–312.
4. Kazanskaya O, Glinka A, del Barco Barrantes I, Stannek P, Niehrs C, et al. (2008) R-spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. Dev Cell 7: 525–534.
5. Kim KA, Zhao J, Andaramani S, Kakitani M, Oshima T, et al. (2006) R-Spondin proteins: a novel link to beta-catenin activation. Cell Cycle 5: 23–26.
6. Nam JS, Park E, Turcotte TJ, Palencia S, Zhan X, et al. (2007) Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. Dev Biol 311: 124–135.
7. Aoki M, Kiyonari H, Nakamura H, Okamoto H (2008) R-spondin2 expression in the apical ectodermal ridge is essential for outgrowth and patterning in mouse limb development. Dev Growth Diff 50: 85–95.
8. Bell SM, Schreiner CM, Wert SE, Mucenski ML, Scott WJ, et al. (2008) R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135: 1049–1058.
9. Friedman MS, Oyserman SM, Haukkonen KD (2009) Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J Biol Chem 284: 14117–14125.
10. Aoki M, Mieda M, Ikeda T, Hamada Y, Nakamura H, et al. (2007) R-spondin3 is required for mouse placental development. Dev Biol 301: 218–226.
11. Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, et al. (2008) The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development. Development 135: 3655–3664.
12. Parma P, Radi O, Vidal V, Chaboissier MC, Dellambra E, et al. (2006) R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet 38: 1304–1309.
13. Blaydon DC, Ishii Y, O'Toole EA, Unsworth HC, Teh MT, et al. (2006) The gene encoding R-spondin 1 (RSPC1), a secreted protein implicated in Wnt signaling, is mutated in inherited anonychia. Nat Genet 38: 1245–1247.

14. Bergmann C, Sendorok J, Anahd D, Thal CT, Ekiel A, et al. (2006) Mutations in the gene encoding the Wnt-signaling component R-spondin 4 (RSPC4) cause autosomal recessive anonychia. Am J Hum Genet 79: 1105–1109.

15. Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781–810.

16. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.

17. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387–396.

18. Kim KA, Kakinuma M, Zhao J, Oshima T, Tang T, et al. (2005) Malignant influence of human R-spondin 1 on the intestinal epithelium. Science 309: 1256–1259.

19. Sato T, Vries RG, Snippert HJ, van der Weyden M, Barker N, et al. (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262–265.

20. Cadigan KM (2008) Wnt/beta-catenin signaling: turning the switch. Dev Cell 15: 201–205.

21. Wei Q, Yokota C, Semenov MV, Doble B, Woodgett J, et al. (2007) R-spondin 1 associates with Wnt receptors and mediate R-spondin signalling. Nature 476: 562–567.

22. Nam JS, Turcotte TJ, Smith PF, Choi S, Yoon JK (2006) Mouse cristin/R-SP1 is a high affinity ligand for LRPs and induces LRP phosphorylation and beta-catenin signaling. Mol Cell Biol 26: 13993–13999.

23. Ellwanger K, Saito H, Clement-Lacroix P, Maltry N, Niedermeyer J, et al. (2007) R-spondin 2 structure and function. Cell Signal 21: 916–925.

24. Kim KA, Kakinuma M, Zhao J, Oshima T, Tang T, et al. (2005) Malignant influence of human R-spondin 1 on the intestinal epithelium. Science 309: 1256–1259.

25. Liu H, Ferguson MM, Wu J, Rovira H, Liu J, et al. (2011) Wnt signaling regulates hepatic metabolism. Cell 146 Suppl: pS19–pS23.

26. Ziemer LT, Pennica D, Levine AJ (2001) Identification of a mouse homolog of the Drosophila FIZZ1 transcription factor as a beta-catenin-independent Wnt-1 responsive gene. Mol Cell Biol 21: 562–574.

27. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1 in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

28. Tanchiyll I, Nusse R (2004) Identification of Wnt responsive genes using a murine mammary epithelial cell line model system. BMC Dev Biol 4: 6.

29. Tice DA, Szeto W, Soloviev I, Rubinfield F, Feng SE, et al. (2002) Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem 277: 13432–13435.

30. Wang J, Lu Y, Wang J, Zhang J, et al. (2008) CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367–10376.

31. Meijer J, Ogusk J, Kreike B, Nuyen D, de Visser KE, et al. (2008) The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 68: 4701–4708.

32. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, et al. (2009) The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4: e6965.

33. Lin S, Sun L, Hui J, Sun W, Zhao R, et al. (2009) Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett 272: 108–117.

34. Kauf A, Williams AGC, Parakova C (2007) Interaction between beta-catenin and JUN promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210–217.

35. Kurowska-Stolarska M, Hube R, Stolarski B, McInnes IB (2010) Interferulin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 268: 29–35.

36. Molenasar AJ, Harris DP, Rajan GH, Pearson ML, Callaghan MR, et al. (2009) The acute-phase protein serum amyloid A3 is expressed in the bovine mammary gland and plays a role in host defence. Biomarkers 14: 26–37.

37. Bommér GT, Feng Y, Iura A, Giordano TJ, Kaick R, et al. (2010) IRIS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRIS1 to the neoplastic phenotype. J Biol Chem 285: 1928–1938.

38. Peyrat JP, Bonnettre J, Venin PH, Jammes H, Beaucart R, et al. (1999) Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors. J Steroid Biochem Mol Biol 37: 823–827.

39. Attisano L, Labbe E (2004) TGFBeta and Wnt pathway cross-talk. Cancer Metastasis Rev 23: 53–61.

40. Dalley L, Ambrozetti D, Mansukhani A, Basilio C (2003) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 14: 233–247.

41. Cheshire DR, Dunn TA, Ewing CM, Luo J, Isaac WB (2004) Activation of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. Cancer Res 64: 2523–2533.

42. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH (2008) The aryl hydrocarbon receptor 6 contributes to cell migration during hypoxia. J Steroid Biochem Mol Biol 37: 823–827.

43. Tao W, Duan D, Huang H, Thomas A, Liu Q, et al. (2011) Overexpression of the retinoic acid-responsive gene Straf in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res 61: 4197–4205.

44. Zhao L, Penalca D, Xu L, Kalejta RF, Levine AJ (2001) A Wnt-1, a novel member of the Rho gene family that is regulated by Wnt-1. Genes Dev 15: 1796–1807.

45. Prieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

46. Tanchiyll I, Nusse R (2004) Identification of Wnt responsive genes using a murine mammary epithelial cell line model system. BMC Dev Biol 4: 6.

47. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

48. Tanchiyll I, Nusse R (2004) Identification of Wnt responsive genes using a murine mammary epithelial cell line model system. BMC Dev Biol 4: 6.

49. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

50. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

51. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.

52. Zieve MG, Moon RT (2005) Stromelysin-1 and mesothelin are differentially regulated by Wnt-1a and Wnt-1b in C57/6Tg mouse mammary epithelial cells. BMC Dev Biol 5: 2.
72. Braeuning A, Kohle C, Buchmann A, Schwarz M (2011) Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci 122: 16–25.
73. Dong JT, Chen C (2009) Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66: 2691–2706.
74. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, et al. (2006) The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 21: 799–809.
75. Xu Q, Akama R, Isaji T, Lu Y, Hashimoto H, et al. (2011) Wnt/beta-catenin signaling down-regulates N-acetylgalactosaminyltransferase III expression: the implications of two mutually exclusive pathways for regulation. J Biol Chem 286: 4310–4318.
76. Zhu LJ, Altmann SW (2005) mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal Biochem 345: 102–109.
77. Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, et al. (2008) Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol 28: 2368–2379.